Ian Johnson

UK molecular diagnostics firm Biofortuna has named Ian Johnson its new chairman, replacing Mark Hurley, who will remain on the board as a non-executive director. Johnson was founder and CEO of Biotrace International. He also is currently non-executive chairman of Celsis Group and Cyprotex, and is an operational advisor for Harwood Private Equity, an investor in Celsis and Cyprotex.